Study of chemotherapy and immunotherapy effects on esophageal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at how the tumor's surroundings change when you receive a combination of chemotherapy and immunotherapy before surgery for esophageal squamous cell carcinoma. The goal is to understand if this treatment approach is effective and how the tumor reacts, which may help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with squamous cell carcinoma of the esophagus (a type of esophageal cancer).
- Your cancer is considered potentially removable with surgery, and you are set to receive chemotherapy and immunotherapy before that surgery.
- You are in reasonably good general health (able to do most daily activities).
- You have not had prior treatment with immunotherapy drugs called checkpoint inhibitors.
- You are willing to provide tissue samples (from a biopsy) and possibly blood samples for this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests a treatment plan that combines chemotherapy and immunotherapy before surgery, followed by radiation and immunotherapy after surgery for people with esophageal squamous cell cancer. It aims to see if this approach helps prevent the cancer from coming back.
This study tests a combination of two chemotherapy drugs (paclitaxel and cisplatin) plus an immunotherapy drug (sintilimab) given before surgery for esophageal cancer. The goal is to see if this approach shrinks the tumor and improves outcomes.
This trial tests combining a type of immunotherapy (adebrelimab) with chemotherapy before surgery, for esophageal cancer that can be removed. The goal is to see if this combo helps shrink the tumor and improve outcomes.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
This trial tests a combination of an immunotherapy drug (sintilimab) and chemotherapy given before and after surgery for esophageal squamous cell carcinoma. The goal is to see if this approach can improve outcomes for patients with resectable tumors in the middle or lower esophagus.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.